Innovent Biologics Withdraws Parsaclisib Filing in China, Halts Development
Innovent Biologics Inc., a leading China-based biotech company (HKG: 1801), has announced the voluntary withdrawal...
Jiangsu Hengrui Licenses Pyrotinib to Dr. Reddy’s for Indian Market
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has entered into a licensing agreement with...
Beijing Joins Jiangxi’s Interferon Volume-Based Procurement Initiative
The Beijing Municipal Medical Insurance Bureau has announced its participation in the Jiangxi-led interferon inter-provincial...
Sanofi Enters Collaboration with Teva for IBD Drug TEV’574 Development
Sanofi (NASDAQ: SNY) has entered into a collaboration agreement with Teva (NYSE: TEVA) for the...
AstraZeneca Reports Positive Phase III Results for Forxiga in Children with Type 2 Diabetes
UK-based AstraZeneca (AZ, NASDAQ: AZN) has announced promising results from the Phase III T2NOW study...
Sandoz Becomes Independent After Spin-Off from Novartis
Switzerland-based generic and biosimilar drug maker Sandoz (SWX: SDZ) officially became a fully independent company...
Eli Lilly Acquires Point Biopharma to Enhance Oncology Portfolio
Eli Lilly (NYSE: LLY) announced last week its agreement to acquire radiopharmaceutical company Point Biopharma...
Sanofi’s Nexviazyme Approved in China as Enzyme Replacement Therapy for Pompe Disease
Sanofi’s (NASDAQ: SNY) next-generation enzyme replacement therapy (ERT), Nexviazyme (avalglucosidase alfa), has received marketing approval...
NMPA and NHC Tighten Regulations on Etomidate and Modafinil
The National Medical Products Administration (NMPA) and the National Health Commission (NHC) have jointly issued...
Hangzhou HealSun Biopharm Secures RMB 200 Million in Series B+ Financing
Hangzhou HealSun Biopharm Co., Ltd., a Chinese contract research organization (CRO) and contract development and...
Viatris to Divest Women’s Health and API Businesses, Offloading 12 Factories and 6,000 Employees
US-based Viatris Inc. (NASDAQ: VTRS) is set to divest its women’s health business, API operations...
Janssen and Sanofi Partner for Development of First-in-Class E. coli Vaccine
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has entered into a strategic...
Takeda Initiates Global Withdrawal of Exkivity Following Phase III Trial Results
Japan-based Takeda (TYO: 4502) has announced the voluntary global withdrawal of its tyrosine kinase inhibitor...
Kyowa Hakko Kirin to Acquire Orchard Therapeutics for $477.6 Million
Japan-based Kyowa Hakko Kirin is poised to acquire UK-headquartered Orchard Therapeutics plc for a total...
PharmaEssentia Announces Licensing Agreement with WuXi Biologics for Antibody Development
Taiwan-based PharmaEssentia Corporation (TPE: 6446, FRA: 8Z1) has entered into a licensing agreement with China’s...
Boehringer Ingelheim Collaborates with Zeiss Medical Technology on Retinal Disease Detection
Germany’s Boehringer Ingelheim (BI) has entered into a collaboration agreement with fellow German firm Zeiss...
Guangdong Medicine Exchange Announces Volume-Based Procurement for Medical Devices
The Guangdong Medicine Exchange has issued three notifications regarding the volume-based procurement (VBP) of medical...
Cardinal Health Acquires MedAlliance for $1.135 Billion to Enhance Vascular Intervention Portfolio
US-based Cardinal Health (NYSE: CAH) has announced the acquisition of Swiss firm MedAlliance for a...
Hong Kong Government Partners with AstraZeneca, Tigermed, and Simcere to Boost Innovation
The government of the Hong Kong Special Administrative Region has entered into significant partnership agreements...
Everest Medicines and Calliditas Present New Data on Nefecon for IgA Nephropathy
Everest Medicines (HKG: 1952), in partnership with Calliditas Therapeutics AB (Nasdaq: CALT), recently presented new...